User contributions for Nehal Eid

12 February 2025

• 11:0111:01, 12 February 2025 diff hist +45 Zenocutuzumab-zbco No edit summary current Tag: Visual edit
• 10:5610:56, 12 February 2025 diff hist −12 Zenocutuzumab-zbco No edit summary Tag: Visual edit
• 10:5610:56, 12 February 2025 diff hist +7,412 N Zenocutuzumab-zbco Created page with "{{DrugProjectFormSinglePage |aOrAn=a |drugClass=HER2-and HER3-directed antibody |indicationType=treatment |indication=It is a bispecific HER2-and HER3-directed antibody indicated for the treatment of: • Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.* • Adults with advanced, unresectable or metastatic pancreatic adenocarc..."
• 10:2010:20, 12 February 2025 diff hist +6,051 N Cosibelimab-ipdl Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |aOrAn=a |drugClass=programmed death ligand-1 (PD-L1) blocking antibody |indicationType=treatment |indication=It is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. |adverseReactions=The most common adverse reactions (≥10%) were fatigue, musculoskeletal pain, rash, diarrhea,..." current
• 09:5609:56, 12 February 2025 diff hist +6,265 N Ensartinib Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |aOrAn=a |drugClass=Kinase inhibitor |indicationType=treatment |indication=It is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor. |adverseReactions=Most common adverse reactions (incidence≥20%) were rash, musculoskeletal pain, constipation, pruritus, cough, nause..." current

31 January 2025

• 19:0319:03, 31 January 2025 diff hist +3,816 N Olezarsen Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |aOrAn=an |drugClass=Oligonucleotide |indicationType=treatment |indication=It is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). |adverseReactions=1-Injection site reactions 2-Decreased platelet count 3-Arthralgia |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>''..." current

30 January 2025

• 18:0818:08, 30 January 2025 diff hist +13 Concizumab No edit summary current
• 18:0318:03, 30 January 2025 diff hist +2 Concizumab No edit summary
• 18:0218:02, 30 January 2025 diff hist +4,434 Concizumab No edit summary
• 17:2117:21, 30 January 2025 diff hist +1,590 Concizumab No edit summary
• 17:1017:10, 30 January 2025 diff hist +946 N Concizumab Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |indicationType=treatment |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</span>''' |blackBoxWarningBody=''<span style="color:#FF0000;">Condition Name:</span>'' (Content) |offLabelAdultGuideSupport=There is limited information regarding ''Off-Label Guideline-Supported Use'' of Concizumab in adult patients. |offLabelAdultNoGuideSupport=There is limited information regarding ''Off-Label Non–Guideline-Supported..."